Alprenolol hydrochloride
Based on 9 publication(s) in Google Scholar
Alprenolol ((RS)-Alprenolol; dl-Alprenolol) hydrochloride is an orally active non-selective β-adrenoceptor antagonist and an antagonist of 5-HT1A and 5-HT1B receptors. Alprenolol hydrochloride is used as an anti-hypertensive, anti-anginal and anti-arrhythmic agent.
For research use only. We do not sell to patients.
- Purity: 99.63%
- CAS No.: 13707-88-5
- Formula: C15H24ClNO2
- Molecular Weight:285.81
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Anti-Obesity Compound Library
HY-L087
-
5-HT Receptor Compound Library
HY-L121
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Off-patent Drug Library
HY-L141
-
Antihypertensive Compound Library
HY-L145
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Alprenolol hydrochloride
More- Nat Commun. 2026 Jan 16;17(1):1795. [Abstract]
- Nat Commun. 2020 Sep 25;11(1):4857. [Abstract]
- Nat Chem Biol. 2024 Jan;20(1):74-82. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- J Pharm Biomed Anal. 2021 Feb 20:195:113870. [Abstract]
- Biochemistry. 2025 Aug 19;64(16):3585-3598. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Jul 1:1227:123804. [Abstract]
- Sci Total Environ. 2024 May 13:933:173244. [Abstract]
- bioRxiv. 2020 Jan.
All 5-HT Receptor Isoforms
More
Biological Activity
|
5-HT1A Receptor |
Alprenolol (i.p., 5 mg/kg) hydrochloride effectively blockes the anxiolytic effects of indorenate and ipsapirone but do not reduce the motor activity in adult male Swiss Webster mice[2].
Alprenolol (intravenous injection, 0.5 or 1.0 mg/kg) can decrease systolic pressure by a mean of 10 mm Hg, diastolic pressure by a mean of 10 mm Hg) hydrochloride and heart rate by 23 beats/min, as well as slightly reduce both myocardial and liver blood flows by mean of 17% and 15% respectively at a dose of 1.0 mg/kg in cats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 13707-88-5
-
Appearance Solid
-
Molecular Weight 285.81
-
Formula C15H24ClNO2
-
Color White to off-white
-
SMILES
OC(COC1=CC=CC=C1CC=C)CNC(C)C.[H]Cl
-
Synonyms
(RS)-Alprenolol hydrochloride; dl-Alprenolol hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
An artificial cell capable of signal transduction mediated by ADRB2 for the regulation of glycogenolysis. [Abstract]2026 Jan 16;17(1):1795. PMID: 41545427 -
Nat Commun
DeSiphering receptor core-induced and ligand-dependent conformational changes in arrestin via genetic encoded trimethylsilyl 1H-NMR probe. [Abstract]2020 Sep 25;11(1):4857. PMID: 32978402 -
Nat Chem Biol
2024 Jan;20(1):74-82. PMID: 37580554 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
J Pharm Biomed Anal
Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]2021 Feb 20:195:113870. PMID: 33453569 -
Biochemistry
Biased Signaling and Its Role in the Genesis of Short- and Long-Acting β2-Adrenoceptor Agonists. [Abstract]2025 Aug 19;64(16):3585-3598. PMID: 40773134 -
J Chromatogr B Analyt Technol Biomed Life Sci
High-throughput screening of LogD by using a sample pooling approach based on the traditional shake flask method. [Abstract]2023 Jul 1:1227:123804. PMID: 37393793 -
Sci Total Environ
Comparison of in vitro membrane permeabilities of diverse environmental chemicals with in silico predictions. [Abstract]2024 May 13:933:173244. PMID: 38750756 -
Solvent & Solubility
DMSO : 100 mg/mL (349.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (174.94 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (7.28 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.28 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 11 mg/mL (38.49 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Himori N, et al. Effects of beta-adrenoceptor blocking agents, pindolol, alprenolol and practolol on blood pressure and heart rate in conscious renal hypertensive dogs. Arch Int Pharmacodyn Ther. 1977 Jan;225(1):152-65. [Content Brief]
[2]. Fernández-Guasti A, et al. Evidence for the involvement of the 5-HT1A receptor in the anxiolytic action of indorenate and ipsapirone. Psychopharmacology (Berl). 1990;101(3):354-8. [Content Brief]
[3]. Parratt JR, et al. Myocardial and haemodynamic effects of the beta-adrenoceptor blocking drug alprenolol (H56/28) in anaesthetized cats. Br J Pharmacol. 1969 Oct;37(2):357-66. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.4988 mL | 17.4941 mL | 34.9883 mL | 87.4707 mL |
| 5 mM | 0.6998 mL | 3.4988 mL | 6.9977 mL | 17.4941 mL | |
| 10 mM | 0.3499 mL | 1.7494 mL | 3.4988 mL | 8.7471 mL | |
| 15 mM | 0.2333 mL | 1.1663 mL | 2.3326 mL | 5.8314 mL | |
| 20 mM | 0.1749 mL | 0.8747 mL | 1.7494 mL | 4.3735 mL | |
| 25 mM | 0.1400 mL | 0.6998 mL | 1.3995 mL | 3.4988 mL | |
| 30 mM | 0.1166 mL | 0.5831 mL | 1.1663 mL | 2.9157 mL | |
| 40 mM | 0.0875 mL | 0.4374 mL | 0.8747 mL | 2.1868 mL | |
| 50 mM | 0.0700 mL | 0.3499 mL | 0.6998 mL | 1.7494 mL | |
| 60 mM | 0.0583 mL | 0.2916 mL | 0.5831 mL | 1.4578 mL | |
| 80 mM | 0.0437 mL | 0.2187 mL | 0.4374 mL | 1.0934 mL | |
| 100 mM | 0.0350 mL | 0.1749 mL | 0.3499 mL | 0.8747 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Alprenolol hydrochloride Related Classifications
HY-B1517A Related Classifications
Powered by Bioz